Patents Assigned to GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
-
Publication number: 20230193208Abstract: Provided is a composition and an application thereof. The composition is used to prepare a medium for inducing differentiation of human pluripotent stem cells to liver precursor cells. By means of screening active components, optimizing the composition ratio and adding a GSK3-beta inhibitor, a Nodal activator, a BMP activator, a BMP inhibitor and a Hedgehog activator, human pluripotent stem cells are induced to differentiate to liver precursor cells. The process is simple and efficient, the content of positive cells is high, and the cost of cell differentiation is reduced. The invention can be used for research and application in drug development and regenerative medicinal treatment, and has broad application prospects.Type: ApplicationFiled: December 19, 2019Publication date: June 22, 2023Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Yinxiong Li, Yuanqi Zhuang, Tingcai Pan, Yan Chen
-
Publication number: 20220251027Abstract: The present application relates to a benzidine compound and an application thereof, the benzidine compound having the structure as shown in formula I below. Further provided in the present application are a pharmaceutically acceptable salt, isomer, racemate, prodrug co-crystal complex, hydrate, and solvate of the compound, as well as an application thereof in the preparation of a drug for the treatment or prevention of ROR?-regulated diseases; more importantly, such a compound can also be used in the preparation of a drug for the treatment of inflammation, immune diseases, cancer and neurological diseases.Type: ApplicationFiled: June 5, 2019Publication date: August 11, 2022Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Yong Xu, Yan Zhang, Xishan Wu, Xiaoqian Xue, Xiaoyu Luo, Yudan Shi, Rui Wang
-
Publication number: 20220186181Abstract: Provided are a culture medium for expanding and cultivating human liver progenitor cells and an application thereof. The chemical components of the formula of the described culture medium are clear, no serum is present, and various components thereof cooperate with each other to synergize. The culture medium is used for the long-term expansion and cultivation of liver progenitor cells in vitro and is used for maintaining the dryness thereof, is beneficial in quickly and efficiently obtaining a large number of functional liver cells, and is suitable for clinical hepatocyte transplantation application as well as for the use of hepatocyte reactors in bioartificial livers.Type: ApplicationFiled: December 19, 2019Publication date: June 16, 2022Applicant: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Yinxiong Li, Tingcai Pan, Yan Chen, Yuanqi Zhuang, Fan Yang
-
Patent number: 11299709Abstract: The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.Type: GrantFiled: January 11, 2018Date of Patent: April 12, 2022Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCESInventors: Jinyong Wang, Rongqun Guo, Mengyun Zhang, Lijuan Liu, Xiaofei Liu, Cui Lv, Juan Du
-
Patent number: 11124557Abstract: Provided in the present invention is a PDL-1 molecule. The affinity of the PDL-1 molecule to the PD-1 molecule is at least two times the affinity of the wild-type PDL-1 molecule to the PD-1 molecule. Meanwhile, the PDL-1 molecule of the present invention can effectively improve the killing efficiency of lymphocytes. In addition, the present invention also provides nucleic acids encoding the PDL-1 molecule of the present invention, and a complex of the PDL-1 molecules of the present invention. The PDL-1 molecule of the present invention may be used alone or in combination with other molecules.Type: GrantFiled: October 9, 2016Date of Patent: September 21, 2021Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Yi Li, Zhaoduan Liang
-
Patent number: 11041184Abstract: A mycobacteriophage capable of delivering an auto-luminescent element includes luxCDABE genes for auto-luminescence of a host bacterium. The auto-luminescent element is located on a transposon, and can be randomly inserted into the host genome with the transposon. The mycobacteriophage can be used for rapid detection of a live host bacterium in a sample and detection of sensitivity of the host bacterium to a drug or drug combination.Type: GrantFiled: September 7, 2018Date of Patent: June 22, 2021Assignee: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Tianyu Zhang, Zhiyong Liu
-
Patent number: 10709729Abstract: Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.Type: GrantFiled: December 23, 2015Date of Patent: July 14, 2020Assignees: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES, GUANGZHOU RIBOBIO CO., LTD.Inventors: Bill Biliang Zhang, Micky Daniel Tortorella, Zhe Wang, Xiuqun Yang, Qiuyun Wang
-
Patent number: 10532987Abstract: The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula I, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes.Type: GrantFiled: February 17, 2015Date of Patent: January 14, 2020Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCEInventors: Baishan Jiang, Tao Nie, Wenling Zhao, Yali Zou, Qiang Ding, Sheng Ding, Donghai Wu
-
Patent number: 10508287Abstract: The present invention relates to a method for inducing the transdifferentiation of B lymphoid cells into T lymphoid cells using transcription factor Hoxb5, and related products and applications thereof. The method of the present invention specifically comprises: introducing Hoxb5, a nucleic acid molecule encoding Hoxb5 or a construct comprising the nucleic acid molecule into the B lymphoid cells to obtain the B lymphoid cells with overexpressed Hoxb5; then implanting the obtained B lymphoid cells into the body of a subject to obtain regenerated T cell progenitor cells by way of transdifferentiation, and then the T cell progenitor cells differentiate into mature T cells with functions. The regenerated T cells obtained using the method of the present invention are not only functionally normal, but also show no risk of tumorigenesis or extremely low risk of tumorigenesis.Type: GrantFiled: December 28, 2016Date of Patent: December 17, 2019Assignee: Guangzhou Institutes of Biomedicine and Health Chinese Academy of SciencesInventors: Jinyong Wang, Dan Yang, Yong Dong, Fangxiao Hu, Qianhao Zhao, Mengyun Zhang, Cui Lv, Ying Wang
-
Patent number: 10493106Abstract: The present invention discloses a method for remolding bone marrow microenvironment in a subject having an impaired bone marrow microenvironment, which comprises implanting a composition comprising isolated mesenchymal stromal cells (MSCs) into the bone marrow cavity of the subject. The method of the present invention successfully remolds the bone marrow microenvironment, recovers the normal hematopoiesis of bone marrow, inhibits/delays the pathological process of leukemia and significantly prolongs the survival period. In addition, the method according to the present invention can be used for the treatment of hematologic tumors such as leukemia and aplastic anemia (AA), which is safe and effective but has no side effects.Type: GrantFiled: January 12, 2018Date of Patent: December 3, 2019Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Jinyong Wang, Chengxiang Xia, Yong Dong, Tongjie Wang, Xiaofei Liu, Juan Du, Yang Geng, Lijuan Liu, Hongling Wu
-
Patent number: 10414744Abstract: Provided are a 4-sulfur pentafluoride phenol compound and a preparation method therefor, and a preparation method for a sulfur pentafluoride substituted benzopyran compound. According to the present invention, sulfur pentafluoride salicylaldehyde with multiple substituent groups is synthesized through a plurality of steps by using sulfur pentafluoride phenol as a raw material, and then the sulfur pentafluoride substituted benzopyran compound is synthesized on this basis. The method is simple and convenient, and low in cost; overcomes the defects that, at present, the number of types of sulfur pentafluoride phenols is small, and the synthesis of various sulfur pentafluoride substituted benzopyran compounds cannot be met; and has wide industrial application prospects.Type: GrantFiled: June 22, 2016Date of Patent: September 17, 2019Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCESInventors: Yanmei Zhang, John J. Talley, Yican Wang, Chuang He, Jiantong Guan, Yongjie Lin, Micky D. Tortorella
-
Patent number: 10370360Abstract: Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.Type: GrantFiled: October 21, 2015Date of Patent: August 6, 2019Assignees: The Board of Regents of the University of Texas System, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of SciencesInventors: Rolf A. Brekken, Ke Ding, Xiaomei Ren, Zhengchao Tu, Zhen Wang, Kristina Y. Aguilera
-
Patent number: 10183010Abstract: The present invention relates to the technical field of medicinal chemistry, and in particular discloses a 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof. The compound and pharmaceutically acceptable salt, isomer, racemate, prodrug, co-crystallized complex, hydrate, and solvate thereof can effectively inhibit the BET bromodomain receptor, and can be used for preparing a medicine for treating cancers, cell proliferative disorders, inflammatory diseases, and autoimmune disorders, sepsis, and viral infections.Type: GrantFiled: January 27, 2016Date of Patent: January 22, 2019Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Yong Xu, Xiaoqian Xue, Yan Zhang, Ming Song
-
Publication number: 20180363007Abstract: The present invention relates to a method for inducing the transdifferentiation of B lymphoid cells into T lymphoid cells using transcription factor Hoxb5, and related products and applications thereof. The method of the present invention specifically comprises: introducing Hoxb5, a nucleic acid molecule encoding Hoxb5 or a construct comprising the nucleic acid molecule into the B lymphoid cells to obtain the B lymphoid cells with overexpressed Hoxb5; then implanting the obtained B lymphoid cells into the body of a subject to obtain regenerated T cell progenitor cells by way of transdifferentiation, and then the T cell progenitor cells differentiate into mature T cells with functions. The regenerated T cells obtained using the method of the present invention are not only functionally normal, but also show no risk of tumorigenesis or extremely low risk of tumorigenesis.Type: ApplicationFiled: December 28, 2016Publication date: December 20, 2018Applicant: Guangzhou Institutes of Biomedicine and Health Chinese Academy of SciencesInventors: Jinyong WANG, Dan YANG, Yong DONG, Fangxiao HU, Qianhao ZHAO, Mengyun ZHANG, Cui LV, Ying WANG
-
Patent number: 10059694Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.Type: GrantFiled: November 18, 2015Date of Patent: August 28, 2018Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen
-
Patent number: 10011819Abstract: Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-? inhibitor, ROCK inhibitor and BMP inhibitor.Type: GrantFiled: February 6, 2013Date of Patent: July 3, 2018Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Guangjin Pan, Duanqing Pei, Lihui Wang, Linli Wang, Yanting Xue
-
Patent number: 9782443Abstract: The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F12 medium; N2 supplement; retinoic acid; and BMP-4.Type: GrantFiled: February 5, 2013Date of Patent: October 10, 2017Assignee: Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of SciencesInventors: Duanqing Pei, Jinglei Cai, Pengfei Liu, Shubin Chen, Yanmei Zhang
-
Publication number: 20170283398Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.Type: ApplicationFiled: November 18, 2015Publication date: October 5, 2017Applicants: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Ke Ding, Jian Ding, Shingpan Chan, Meiyu Geng, Xiaomei Ren, Hua Xie, Zhengchao Tu, Yi Chen
-
Patent number: 9770432Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.Type: GrantFiled: June 14, 2016Date of Patent: September 26, 2017Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of SciencesInventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu
-
Patent number: 9763914Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.Type: GrantFiled: June 14, 2016Date of Patent: September 19, 2017Assignee: Guangzhou Institutes of Biomedicine And Health, Chinese Academy of SciencesInventors: Yanmei Zhang, John Jeffrey Talley, Mark G. Obukowicz, Zhengchao Tu, Micky Tortorella, Yican Wang, Jianqi Liu, Yan Chen, Xiaorong Liu, Xin Lu